stockrowGrifols, S.A. (GRFS) vs MIRA Pharmaceuticals, Inc. (MIRA)
- Grifols, S.A. GRFS 8.43 −0.35%
- MIRA Pharmaceuticals, Inc. MIRA 0.57 +5.56%
Grifols, S.A. and MIRA Pharmaceuticals, Inc. are both Drug Manufacturers General companies. Grifols, S.A. is the larger, with a market value of $2.2B against $22.7M — 96.0× the size. MIRA Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Grifols, S.A. trades at 18.2×. Grifols, S.A. has the higher net margin (6.02% vs 0.00%) and the higher return on invested capital (4.76% vs −12,016.1%). Across the 14 metrics below, Grifols, S.A. leads on 10 and MIRA Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | GRFS | MIRA | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.55% | — | 73.01% |
| Operating margin | 16.69% | 0.00% | 18.34% |
| Net margin | 6.02% | 0.00% | 7.31% |
| Free cash flow margin | 8.51% | 0.00% | 18.56% |
| Return on equity | 5.80% | (710.85%) | 5.80% |
| Return on assets | 2.28% | (684.27%) | 2.28% |
| Return on invested capital | 4.76% | (12,016.10%) | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack